Hepatitis - Other Infections
Nov
2026
Description
This session focuses on chronic hepatitis D (delta), covering emerging therapies (bulevirtide, lonafarnib, novel entry inhibitors) and international epidemiologic data.
Presentations
2:00 PM
- 2:15 PM
Convention Center - Bluebird Ballroom 2DEF
Brelovitug Monotherapy for the Treatment of Chronic Hepatitis D: Results from Beyond Week 24 Treatment in the AZURE-1 Phase 2b Study
Douglas T Dieterich, MD, FAASLD | Abstract Presenter
2:15 PM
- 2:30 PM
Convention Center - Bluebird Ballroom 2DEF
Efficacy of elebsiran (VIR-2218) + tobevibart (VIR-3434) in participants with chronic hepatitis delta infection: Patterns of HDV RNA responses through Week 96
Tarik Asselah | Abstract Presenter
2:30 PM
- 2:45 PM
Convention Center - Bluebird Ballroom 2DEF
PREVALENCE AND OUTCOMES OF VIROLOGICAL BREAKTRHOUGHS DURING BULEVIRTIDE MONOTHERAPY IN CHD PATIENTS: A POOLED ANALYSIS FROM THE SAVE-D AND D-SHIELD MULTICENTER STUDIES
Elisabetta Degasperi | Abstract Presenter
2:45 PM
- 3:00 PM
Convention Center - Bluebird Ballroom 2DEF
Hepatic recompensation, safety and viral suppression in patients with advanced decompensated chronic hepatitis Delta treated with bulevirtide: a multicenter experience in ERN VALDIG Centers
Magdalena Meszaros, MD | Abstract Presenter
3:00 PM
- 3:15 PM
Convention Center - Bluebird Ballroom 2DEF
Durable and newly emergent treatment response during a 24-week follow-up in a finite lonafarnib treatment regimen: extended analyses from the phase 3 D-LIVR trial
Tarik Asselah | Abstract Presenter
3:15 PM
- 3:30 PM
Convention Center - Bluebird Ballroom 2DEF
Final Results of the DDR Spain Project: Contemporary Epidemiology and Clinical Profile of Hepatitis Delta Virus Infection in Spain
Federico Garcia | Abstract Presenter
